1978
DOI: 10.1093/bja/50.11.1131
|View full text |Cite
|
Sign up to set email alerts
|

Pancuronium Pharmacokinetics in Patients With Liver Cirrhosis

Abstract: The serum and urinary concentrations of pancuronium were measured in 14 surgical patients with cirrhosis and 12 patients free from liver disease undergoing abdominal surgery. A two-compartment open model was used in the pharmacokinetic analysis of the data. A two-fold increase in both the distribution half-life (T 1/2 alpha) from 11 min to 24 min and in the elimination half-life (T 1/2 beta) from 114 min to 208 min was observed in patients with cirrhosis. In these individuals, the total apparent volume of dist… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
24
0
1

Year Published

1981
1981
2024
2024

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 95 publications
(25 citation statements)
references
References 0 publications
0
24
0
1
Order By: Relevance
“…We also had success using pancuronium, a common, readily available nondepolarizing paralytic agent. The benefits of pancuronium are its rapid onset of action, longer duration of action, extended shelf life, and low cost (5,8). Pancuronium showed no significant cardiac effects as long as exposure was limited to 30 min or less.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…We also had success using pancuronium, a common, readily available nondepolarizing paralytic agent. The benefits of pancuronium are its rapid onset of action, longer duration of action, extended shelf life, and low cost (5,8). Pancuronium showed no significant cardiac effects as long as exposure was limited to 30 min or less.…”
Section: Discussionmentioning
confidence: 99%
“…Pancuronium bromide is an aminosteroidal competitive neuromuscular blocker that requires renal excretion and is partially metabolized by the liver. In humans, pancuronium bromide causes a dose-dependent increase in heart rate accompanied by increases in cardiac output and blood pressure due to sympathomimetic properties (5,8). Doses of the paralytic medications were chosen to achieve rapid onset of paralysis while minimizing the duration of effect.…”
Section: Methodsmentioning
confidence: 99%
“…Therefore, we do not believe that pancuronium failed to produce muscle relaxation because of the presence of myotonic contracture. Specific pathologic states cause increased resistance to nondepolarizing muscle relaxants, e.g., upper motor neuron lesion [10], disuse atrophy [11], severe thermal injuries [12], and liver cirrhosis [13]. However, our patient was not in any of these pathologic states.…”
Section: Discussionmentioning
confidence: 85%
“…Les deux conséquences cliniques sont donc la nécessité éventuelle d'augmenter la dose initiale pour obtenir un relâchement musculaire satisfaisant, et un risque de prolongation de la durée de son action. On observe un phénomène de résis-tance à la curarisation et un allongement important de la durée des effets thérapeutiques [40]. Vécuronium.…”
Section: Les Curaresunclassified